Brief: Rigel Pharmaceuticals Has Received Deficiency Letter From Listing Qualifications Department Of Nasdaq
29/11/2022 21:37
Nov 29 (Reuters) - Rigel Pharmaceuticals Inc RIGL.O :
* ON NOV 22, CO RECEIVED DEFICIENCY LETTER FROM LISTING
QUALIFICATIONS DEPARTMENT OF THE NASDAQ STOCK MARKET LLC
* NOTIFICATION RECEIVED HAS NO IMMEDIATE EFFECT ON RIGEL’S
NASDAQ
LISTING
* RIGEL’S COMMON STOCK WILL CONTINUE TO TRADE ON NASDAQ
UNDER THE
SYMBOL “RIGL” AT THIS TIME
Further company coverage: RIGL.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)